Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CELC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Gedatolisib FDA approved Jul 2026 · Revtorpyk |
Breast Cancer | Phase 3 · NCT05501886 | Active not recruiting |
| Doxorubicin | HER2-negative Breast Cancer | Phase 2 · NCT03412643 | Unknown |
| Samotolisib (LY3023414) | Endometrial Cancer | Phase 2 · NCT03675893 | Recruiting |
| Metformin | Endometrial Cancer | Phase 2 · NCT03675893 | Recruiting |
| Weekly Paclitaxel | HER2-negative Breast Cancer | Phase 2 · NCT03412643 | Unknown |
Also used in these trials (approved or third-party drugs, not CELC's own candidates): Alpelisib, Palbociclib, Fulvestrant, Letrozole, Capmatinib, Cyclophosphamide, Darolutamide, Neratinib, Abemaciclib, Pertuzumab, Talazoparib, Trastuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CELC holds $754M in cash and short-term investments (as of Jun 30, 2026) and burns about $55.2M/quarter from operations, an estimated runway of 40.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
Based on our current business plan, we believe that our current cash, cash equivalents and short-term investments, will provide sufficient cash to finance our operations at least into 2029.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP Former 10% owner |
Insider | 4,372,852 | 8.94% | 2026-07-14 |
| Brian F. Sullivan Chief Executive Officer, Director · +1.50M options |
Insider | 3,200,983 | 6.54% | 2026-08-14 |
| BANK OF AMERICA CORP /DE/ | Institution (13G, 5%+) | 3,170,198 | 6.48% | 2026-06-30 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 3,160,200 | 6.46% | 2025-12-31 |
| Avoro Capital Advisors LLC | Institution (13G, 5%+) | 3,111,111 | 6.36% | 2025-12-31 |
| RTW Investments, LP | Institution (13G, 5%+) | 3,039,621 | 6.21% | 2026-03-31 |
| Blackrock Inc. | Institution (13F) | 3,018,785 | 6.17% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 1,955,304 | 4.00% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 1,874,137 | 3.83% | 2026-06-30 |
| NEA Management Company, LLC | Institution (13F) | 1,710,561 | 3.50% | 2026-06-30 |
| Soleus Capital Management, L.P. | Institution (13F) | 1,704,318 | 3.48% | 2026-06-30 |
| Bank of America Corporation | Institution (13F) | 1,471,307 | 3.01% | 2026-06-30 |
Share count 48,931,908 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-14 filed 2026-08-18 |
Hahne Vicky |
Award (A) | 16,000 | – | 37,808 |
| 2026-08-14 filed 2026-08-18 |
Hahne Vicky |
Option award (A) | 10,000 | – | – |
| 2026-08-14 filed 2026-08-18 |
Sullivan Brian F. |
Award (A) | 80,000 | – | 1,450,199 |
| 2026-08-14 filed 2026-08-18 |
Sullivan Brian F. |
Option award (A) | 120,000 | – | – |
| 2026-08-14 filed 2026-08-18 |
Laing Lance G. |
Option award (A) | 10,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-07-17 | REVTORPYK™ (gedatolisib) | NDA | +0.1% | +0.1% | — |
| 2026-05-01 | — | sNDA | +6.3% | +3.5% | +7.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →